Blueprint Medicines Corp - BPMC STOCK NEWS

Blueprint Medicines Corporation (NASDAQ: BPMC) recently presented significant data at the 62nd American Society of Hematology Annual Meeting, focusing on systemic mastocytosis (SM). Their investigational therapy, AYVAKIT, is notable for achieving a 75% overall response rate and a 36% complete remission rate in advanced SM patients. The company plans to submit a supplemental new drug application to the FDA for AYVAKIT this month. Additionally, new diagnostic tools highlighted the urgent need for improved SM diagnosis, underscoring the severe impact of this rare disease on patient quality of life.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the granting of non-qualified stock options for 16,354 shares and 8,174 restricted stock units (RSUs) to eight new employees, effective December 1, 2020. This grant is part of the 2020 Inducement Plan, adhering to NASDAQ Listing Rule 5635(c)(4). The stock options have an exercise price of $105.65 per share, matching the closing price on the grant date. Vesting schedules for both options and RSUs are detailed, ensuring employee retention as they vest based on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) has received FDA approval for GAVRETO™ (pralsetinib), a targeted therapy for patients with RET-altered thyroid cancers. This accelerated approval includes adult and pediatric patients with advanced RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral therapy designed to selectively target RET alterations in various tumors. The approval is based on efficacy data from the Phase 1/2 ARROW trial, which showed a 60% overall response rate in RET-mutant MTC patients.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced plans to present data on AYVAKIT™ (avapritinib) at the 62nd American Society of Hematology (ASH) Annual Meeting on December 6-7, 2020. These presentations illustrate the medical needs in systemic mastocytosis (SM) and the potential impact of AYVAKIT across various patient groups. AYVAKIT targets the D816V mutant KIT, a key driver of SM. The company emphasizes its commitment to improving SM diagnosis and treatment through collaborative efforts.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of stock options and restricted stock units (RSUs) to five new employees effective November 1, 2020. The total includes 16,513 stock options and 8,255 RSUs, awarded under the 2020 Inducement Plan. The options have an exercise price of $102.28, matching the stock's closing price on October 31, 2020. Options and RSUs will vest incrementally over time, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ:BPMC) reported strong Q3 2020 financial results, achieving $745.1 million in total revenues. The net income surged to $634.0 million, or $11.16 per diluted share, compared to a net loss of $94.3 million in Q3 2019. Key product revenue included $6.1 million from AYVAKIT and $0.2 million from GAVRETO. The company expects significant growth with the upcoming supplemental NDA for AYVAKIT and the potential U.S. approval of GAVRETO for RET-altered thyroid cancers by February 2021, strengthening its market position.

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on October 29, 2020 at 8:30 a.m. ET to discuss its third-quarter 2020 financial results and provide a corporate update. Investors can access the call by dialing (855) 728-4793 domestically or (503) 343-6666 internationally, using conference ID 2995408. A webcast will be available post-call on the Blueprint Medicines website. The company specializes in precision therapies targeting genomically defined cancers, rare diseases, and cancer immunotherapy.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on October 2, 2020, that it granted non-qualified stock options and restricted stock units (RSUs) to five new employees, effective October 1, 2020. The total grants comprise 77,118 stock options and 38,557 RSUs, including a significant award to the new President of Research & Development, Fouad Namouni, M.D. The options have an exercise price of $93.93, aligning with the stock's closing price on the grant date. These grants are part of the 2020 Inducement Plan designed to attract new talent in alignment with NASDAQ listing rules.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced that the European Commission has granted conditional marketing authorization for AYVAKYT® (avapritinib) to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with the PDGFRA D842V mutation. This marks the first approved therapy in Europe targeting this specific mutation. AYVAKYT showed a remarkable 95% overall response rate in the NAVIGATOR trial. The company plans to launch the drug initially in Germany, with subsequent launches in other countries based on local reimbursement.